Pain relief with lidocaine 5% patch in localized peripheral neuropathic pain in relation to pain phenotype: A randomised, double-blind, and placebo-controlled, phenotype panel study

Pain

Volumn 156, Issue 11, 2015, Pages 2234-2244

  Demant, Dyveke T ^a   Lund, Karen ^b   Finnerup, Nanna B ^b   Vollert, Jan ^c   Maier, Christoph ^c   Segerdahl, Märtha S ^d,e   Jensen, Troels S ^b   Sindrup, Søren H ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d H LUNDBECK A S   (Denmark)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Lidocaine; Pain phenotype; Peripheral neuropathic pain; Treatment

Indexed keywords

LIDOCAINE; PLACEBO; LOCAL ANESTHETIC AGENT;

ADULT; ANALGESIA; ARTICLE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEEP ACHING PAIN; FEMALE; HUMAN; HYPERSENSITIVITY; INTENTION TO TREAT ANALYSIS; IRRITABLE NOCICEPTOR; MALE; NERVE INJURY; NEUROPATHIC PAIN; NONIRRITABLE NOCICEPTOR; PAIN; PAIN ASSESSMENT; PAIN PAROXYSM; PAIN RECEPTOR; PERIPHERAL NEUROPATHIC PAIN; PHENOTYPE; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; TREATMENT DURATION; AGED; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; HYPERALGESIA; MIDDLE AGED; NEURALGIA; PAIN MEASUREMENT; PAIN THRESHOLD; PATHOPHYSIOLOGY; PHYSIOLOGY; QUESTIONNAIRE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANESTHETICS, LOCAL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERALGESIA; LIDOCAINE; MALE; MIDDLE AGED; NEURALGIA; NOCICEPTORS; PAIN MEASUREMENT; PAIN THRESHOLD; PHENOTYPE; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84964627219     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1097/j.pain.0000000000000266     Document Type: Article

References (29)

1. Amir R, Liu CN, Kocsis JD, Devor M. Oscillatory mechanism in primary sensory neurons. Brain 2002;125:421-35.
2. Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, Nurmikko T. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113-e88.
3. Barbano RL, Herrmann DN, Hart-Gouleau S, Pennella-Vaughan J, Lodewick PA, Dworkin RH. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol 2004;61:914-8.
4. Baron R, Förster M, Binder A. Subgrouping of patients with neuropathic pain according to pain-related sensory abnormalities: a first step to a stratified treatment approach. Lancet Neurol 2012;11: 999-1005.
5. Baron R, Tölle TR, Gockel U, Brosz M, Freynhagen R. A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: differences in demographic data and sensory symptoms. PAIN 2009;146:34-40.
6. Binder A, Bruxelle J, Rogers P, Hans G, Bösl I, Baron R. Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Investig 2009;29:393-408.
7. Bischoff JM, Petersen M, Üceyler N, Sommer C, Kehlet H, Werner MU. Ladocaine patch (5%) in the treatment of persistent inguinal postherniorrhaphy pain. A randomized, double-blind, placebocontrolled, crossover trial. Anesthesiology 2013;119:1444-52.
8. Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E, Rostaing S, Lanteri-Minet M, Collin E, Grisart J, Boureau F. Development and validation of the Neuropathic Pain Symptom Inventory. PAIN 2004; 108:248-57.
9. Cheville AL, Sloan JA, Northfelt DW, Jillella AP, Wong GY, Bearden III JD, Liu H, Schaefer PL, Marchello BT, Christensen BJ, Loprinzi CL. Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind cross-over study (N01CB). Support Care Cancer 2009;17:451-60.
10. Demant D, Lund K, Vollert J, Maier C, Segerdahl M, Finnerup N, Jensen TS, Sindrup SH. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebocontrolled, phenotype stratified study. PAIN 2014;155:2263-73.
11. Fields HL, Rowbotham M, Baron R. Postherpetic neuralgia: irritable nociceptors and deafferentiation. Neurobiol Dis 1998;5:209-27.
12. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpää M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice ASC, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015;14:162-73.
13. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. PAIN 2010;150:573-81.
14. Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. PAIN 1999;80: 533-38.
15. Gammaitoni AR, Alvarez NA, Bradley SG. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the litterature. J Clin Pharmacol 2003;43:111-7.
16. Ho KY, Huh BK, White WD, Yeh CC, Miller EJ. Topical amitriptyline versus lidocaine in the treatment of neuropathic pain. Clin J Pain 2008;24:51-5.
17. Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice AS, Treede RD. A new definition of neuropathic pain. PAIN 2011;152:2204-5.
18. Jensen TS, Finnerup NB. Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms. Lancet Neurol 2014;13:924-35.
19. Krumova EK, Zeller M, Westermann A, Maier C. Lidocaine patch (5%) produces a selective, but incomplete block of Ad and C fibers. PAIN 2012; 153:273-80.
20. Madsen CS, Johnsen B, Fuglsang-Frederiksen A, Jensen TS, Finnerup NB. Differential effects of a 5% lidocaine medicated patch in peripheral nerve injury. Muscle Nerve 2013;48:265-71.
21. Magerl W, Krumova EK, Baron R, Tölle T, Treede RD, Maier C. Reference data for quantitative sensory testing (QST): refined stratification for age and a novel method for statistical comparison of group data. PAIN 2010; 151:598-605.
22. Maier C, Baron R, Tölle TR, Binder A, Birbaumer N, Birklein F, Gierthmühlen J, Flor H, Geber C, Huge V, Krumova EK, Landwehrmeyer GB, Magerl W, Maihöfner C, Richter H, Rolke R, Scherens A, Schwarz A, Sommer C, Tronnier V, Uç eyler N, Valet M, Wasner G, Treede RD. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. PAIN 2010;150:439-50.
23. Meier T, Wasner G, Faust M, Kuntzer T, Ochsner F, Hueppe M, Bogousslavsky J, Baron R. Efficacy of lidocaine patch 5%in the treatment of focal peripheral neuropathic pain syndromes: a randomized, doubleblind, placebo-controlled study. PAIN 2003;106:151-8.
24. Pfau DB, Krumova EK, Treede RD, Baron R, Toelle T, Birklein F, Eich W, Geber C, Gerhardt A, Weiss T, Magerl W, Maier C. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): reference data for the trunk and application in patients with chronic postherpetic neuralgia. PAIN 2014;155:1002-15.
25. Rolke R, Baron R, Maier C, Tölle TR, Treede RD, Beyer A, Binder A, Birbaumer N, Birklein F, Bötefür IC, Braune S, Flor H, Huge V, Klug R, Landwehrmeyer GB, Magerl W, Maihöfner C, Rolko C, Schaub C, Scherens A, Sprenger T, Valet M, Wasserka B. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. PAIN 2006;123:231-43.
26. Rowbotham MC, Davies PS, Fields HL. Topical lidocaine gel relieves postherpetic neuralgia. Ann Neurol 1995;37:246-53.
27. Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: double-blind controlled study of a new treatment method for postherpetic neuralgia. PAIN 1996;65:39-44.
28. Sindrup SH, Jensen TS. Are sodium channel blockers useless in peripheral neuropathic pain? PAIN 2007;128:6-7.
29. Wasner G, Kleinert A, Binder A, Schattschneider J, Baron R. Postherpetic neuralgia: topical lidocaine is effective in nociceptor-deprived skin. J Neurol 2005;252:677-86.